An comparison of acute toxicities and patient-reported outcomes between intensity-modulated proton therapy and volumetric-modulated arc therapy after ipsilateral radiation for head and neck cancers

Head Neck. 2022 Feb;44(2):359-371. doi: 10.1002/hed.26937. Epub 2021 Dec 3.

Abstract

Background: Intensity-modulated proton therapy (IMPT) demonstrates superior dose distribution over volumetric-modulated arc therapy (VMAT) for sparing organs-at-risk (OARs) in ipsilateral radiotherapy. To determine a clinical benefit, assessment of patient-reported outcomes (PRO) and physician-reported toxicities alongside a dosimetric analysis is needed.

Methods: Plans were analyzed for dosimetric differences. PROs were compared for patients undergoing ipsilateral curative-intent radiotherapy for tonsil and salivary gland cancers with VMAT or IMPT from 2015 to 2020. Physician-reported toxicities were compared.

Results: In 40 patients, IMPT was associated with decreased dose to multiple OARs and less deterioration in the following PROs: pain, swallowing function, dry mouth, sticky saliva, sensory change, cough, speech, feeling ill, and social eating. Physician-reported toxicities demonstrated less oral pain.

Conclusion: IMPT is associated with decreased dose to OARs and less patient-reported acute deterioration in multiple head and neck domains. A strong consideration for IMPT in ipsilateral head and neck patients with cancer is warranted.

Keywords: IMPT; head and neck cancer; ipsilateral neck radiotherapy; proton radiotherapy; tonsil and salivary cancer.

MeSH terms

  • Head and Neck Neoplasms* / etiology
  • Head and Neck Neoplasms* / radiotherapy
  • Humans
  • Organs at Risk
  • Patient Reported Outcome Measures
  • Proton Therapy* / adverse effects
  • Radiotherapy Dosage
  • Radiotherapy Planning, Computer-Assisted
  • Radiotherapy, Intensity-Modulated* / adverse effects